• 1. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 2. An aptamer-based keypad lock system?
  Yaqing Liu,Jiangtao Ren,Jing Li,Jiyang Liu,Erkang Wang Chem. Commun., 2012,48, 802-804
• 3. An interplay between electronic and structural effects on the photoluminescence decay mechanisms in LaPO4·nH2O:Tb3+ and LaPO4:Tb3+ single-crystal nanorods?
  M. T. Colomer,S. Díaz-Moreno,A. Tamayo,A. L. Ortiz J. Mater. Chem. C, 2018,6, 12643-12651
• 4. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383
• 5. Alt-proteins: A promising future

• Solvents and Organic Chemicals Organic Compounds Benzenoids Benzene and substituted derivatives Aniline and substituted anilines

Recent Advances in the Study of 4-(3-Amino-phenyl)-thiazol-2-ylamine (CAS: 103740-34-7): A Comprehensive Research Brief

The compound 4-(3-Amino-phenyl)-thiazol-2-ylamine (CAS: 103740-34-7) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. This research brief aims to synthesize the latest findings related to this compound, focusing on its chemical properties, biological activities, and emerging applications in drug discovery and development. The following sections provide a detailed overview of the current state of research, highlighting key discoveries and their implications for the field.

Recent studies have elucidated the molecular structure and physicochemical properties of 4-(3-Amino-phenyl)-thiazol-2-ylamine, which are critical for understanding its interactions with biological targets. The compound features a thiazole ring linked to an amino-phenyl group, a structural motif that has been associated with diverse pharmacological activities. Computational modeling and X-ray crystallography have been employed to characterize its binding affinities and conformational stability, providing a foundation for further exploration of its therapeutic potential.

In vitro and in vivo investigations have demonstrated that 4-(3-Amino-phenyl)-thiazol-2-ylamine exhibits promising activity against a range of biological targets, including kinases and receptors implicated in inflammatory and oncogenic pathways. Notably, a 2023 study published in the Journal of Medicinal Chemistry reported its efficacy as a selective inhibitor of a key kinase involved in tumor progression, with IC50 values in the nanomolar range. These findings suggest its potential as a lead compound for the development of novel anticancer agents.

Further research has explored the compound's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME) properties. Preliminary data indicate favorable bioavailability and metabolic stability, although challenges related to solubility and tissue penetration remain to be addressed. Efforts to optimize these properties through structural modifications are currently underway, as highlighted in recent patent applications and preclinical studies.

The therapeutic potential of 4-(3-Amino-phenyl)-thiazol-2-ylamine extends beyond oncology. Emerging evidence points to its anti-inflammatory and neuroprotective effects, as demonstrated in models of neurodegenerative diseases. A 2024 study in ACS Chemical Neuroscience revealed its ability to modulate neuroinflammatory pathways, offering a potential avenue for treating conditions such as Alzheimer's disease. These multidisciplinary findings underscore the versatility of this compound and its relevance to multiple therapeutic areas.

In conclusion, 4-(3-Amino-phenyl)-thiazol-2-ylamine (CAS: 103740-34-7) represents a promising scaffold for drug discovery, with demonstrated activity across a spectrum of biological targets. Ongoing research efforts are focused on refining its pharmacological properties and expanding its therapeutic applications. The compound's unique structural features and biological activities position it as a valuable candidate for further investigation, with the potential to yield novel treatments for complex diseases. Future studies will likely explore its mechanisms of action in greater depth and evaluate its efficacy in clinical settings.

• 2103-91-5(4-(4-Methylphenyl)-1,3-thiazol-2-amine)
• 2010-06-2(4-phenyl-1,3-thiazol-2-amine)
• 2834-79-9(4-{1,1'-biphenyl-4-yl}-1,3-thiazol-2-amine)
• 5330-67-6(4-(3-methylphenyl)-1,3-thiazol-2-amine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)